EPR – Emergency Preservation and Resuscitation


EPR-Technologies is a biomedical spinoff of the Safar Center for Resuscitation Research, University of Pittsburgh, and is committed to the preservation of human life through rapid profound hypothermia by introducing patented products for “Emergency Preservation and Resuscitation” (EPR) to save a life when standard cardiopulmonary resuscitation (CPR) fails. The Company is a Delaware registered corporation formed to commercialize specialized technology for induction of rapid profound hypothermia and delayed resuscitation developed at the Safar Center.

Over the past 10-12 years, the U.S. Army has invested $14.75 million in grants for R&D including funds for the planned early-2013 clinical trial.  The U.S. Army shares no ownership in EPR technology or patents. The emergency medical market base for the sale of EPR products to save victims’ lives following traumatic exsanguination cardiac arrest and sudden cardiac arrest (SCA) unresponsive to defibrillation is approximately 1,600 victims per day (350 trauma and 1250 SCA) in the U.S. alone. Approximately, one victim per minute. For all other industrialized nations, the number of cases of trauma and SCA victims is estimated to be 3.5-4.5 times U.S. numbers.

EPR is critical to save lives currently unrecoverable when CPR fails. EPR-Technologies utilizes the revolutionary emergency resuscitation capabilities developed by the Safar Center over the past two decades to form the basis of the technology and “know-how” for a product line to support novel, advanced, lifesaving, emergency medical procedures. EPR-Technologies is dedicated to the memory and vision of the founder of the Safar Center, Dr. Peter Safar, M.D., to advance emergency medical resuscitation capabilities in order “to save hearts and brains too good to die”. Dr. Safar was a pioneer in resuscitation research, “the father of cardiopulmonary resuscitation” (CPR) (mouth-to-mouth breathing and chest compressions), and a world leader for public access to basic resuscitation procedures. His ongoing Safar Center team and EPR-Technologies continue the dedication and work in the advanced resuscitation procedures of EPR.

EPR-Technologies, Inc. plans to introduce novel, emergency medical procedures that will support the rapid use of profound-to-ultraprofound hypothermia in previously unrecoverable patients inducing a three (3) hour state of tolerance to lack of oxygen for any cause of cardiac arrest, like massive bleeding from auto accidents, gunshot wounds and even massive heart attacks, thereby buying time for lifesaving interventions. ULTIMATELY, EPR WILL BECOME THE NEXT EMERGENCY LIFE-SAVING “STANDARD OF CARE” PROCEDURE FOLLOWING THE FAILURE OF CPR ON ANY VICTIM.


The Company’s products and services fall within the following EPR categories and stages for sequential training, system readiness, and emergency use as listed: (1) EPR Catheter Kits; (2) EPR Cold Energy Flush Solutions; (3)  EPR Refrigerator and Pump Systems for Hospital and Field Use; and (4) EPR Education, Training, and Certification for Physicians and Paramedics/

The initial products contained in the above EPR-Kits, EPR Cold Energy Flush Solutions, EPR Refrigerator and Pump System, and the related techniques and procedures will require FDA 501(k) pre-market notification and approval after successful EPR clinical trials.  EPR products and technology support the rapid use of profound hypothermia in previously unrecoverable patients inducing a 3+ hour tolerance to ischemia for any cause of cardiac arrest, thereby buying time for lifesaving interventions.

During this protected, hypothermic, time period, the patient has no cardiac (no heart beat), no respiratory (no breathing), and no cerebral functions. Profound hypothermia in currently unresuscitable patients followed by delayed resuscitation is our unique brand in the marketplace. EPR is currently the only alternative to death when CPR fails.

Leave a Reply